LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin, 2017, 67: 7-30.

DeSantis C, Ma J, Bryan L, Ahmedin J. Breast cancer statistics, 2013. CA Cancer J Clin, 2014, 64: 52-62.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med, 2010, 363: 1938-1948.

Cetin I, Topcul M. Triple negative breast cancer. Asian Pac J Cancer Prev, 2014, 15: 2427-2431.

Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res, 2008, 14: 8010-8018.

Bosch A, Eroles P, Zaragoza R, Vina JR, Liuch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev, 2010, 36: 206-215.

Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet, 2006, 15: R17-R29.

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet, 2011, 12: 861-874.

Spizzo R, Almeida MI, Colombatti A, Calin CA. Long non-coding RNAs and cancer: a new frontier of translational research. Oncogene, 2012, 31: 4577-4587.

Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol, 2012, 9: 703-719.

Liang WC, Ren JL, Wong CW, Shan SO, Waye MM, Fu WM, Zhang JF. LncRNA-NEF antagonized epithelial to mesenchymal transition and cancer metastasis via cis-regulating FOXA2 and inactivating Wnt/β-catenin signaling. Oncogene, 2018, 37: 1445-1456.

Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, 2014, 33: 679-689.

Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, Di Leva G. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol, 2009, 35: 393-400.

Shen X, Xie B, Ma Z, Yu W, Wang W, Xu D, Yan X. Identification of novel long non-coding RNAs in triple-negative breast cancer. Oncotarget, 2015, 6: 21730-21739.

Chen C, Li Z, Yang Y, Xiang T, Song W, Liu S. Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer. Cancer Biol Ther, 2015, 16: 856-865.

Han J, Han B, Wu X, Hao J, Dong X, Shen Q, Pang H. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharmacol, 2018, 359: 55-61.

Li DY, Chen WJ, Luo L, Wang YK, Shang J, Zhang Y, Chen G. Prospective lncRNA-miRNA-mRNA regulatory network of long non-coding RNA LINC00968 in non-small cell lung cancer A549 cells: a miRNA microarray and bioinformatics investigation. Int J Mol Med, 2017, 40: 1895-1906.

Yu Y, Nangia-Makker P, Farhana L, Majumdar APN. A novel mechanism of lncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Mol Cancer, 2017, 16:

Zhang J, Hu SL, Qiao CH, Ye JF, Li M, Ma HM, Wang JH. LncRNA-NEF inhibits proliferation, migration and invasion of esophageal squamous-cell carcinoma cells by inactivating wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci, 2018, 22: 6824-6831.

Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, Cai H. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling. J Clin Endocrinol Metab, 2013, 98: E1305-E1313.